Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848301 | 1.00 | PPARG (0.53) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848256 | 0.95 | PPARG (0.47) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848257 | 0.95 | PPARG (0.47) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848169 | 0.94 | PPARG (0.62) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848178 | 0.94 | PPARG (0.62) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848304 | 0.91 | PPARG (0.52) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848307 | 0.91 | PPARG (0.52) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17848311 | 0.87 | PPARG (0.56) | PPARGSMN1; SMN2HPGDPOLBALDH1A1 | |
| SCHEMBL17848269 | 0.87 | PPARG (0.56) | PPARGSMN1; SMN2HPGDPOLBALDH1A1 | |
| SCHEMBL17848245 | 0.85 | PPARG (0.46) | PPARGKMT2AMEN1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | claimed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | KRAS, NRAS, HRAS | PPARG 2635/4885KMT2A 2124/4885MEN1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.